TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03518645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPN strategy
Description: Predilatation with OPN balloon will be performed as a lesion preparation for BVS Absorb implantation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard strategy
Description: Predilatation with standard balloon will be performed as a lesion preparation for BVS Absorb implantation.
Study: NCT02770898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Holistic Health
Description: Interventions for probationers will aim to promote physical and psychosocial health, family relationships and Family 3H (happiness, harmony and health).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Holistic Health
Description: Interventions for probationers will aim to promote physical and psychosocial health, family relationships and Family 3H (happiness, harmony and health).
Study: NCT00747032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NYC 0462 Ointment
Description: To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
Study: NCT02487225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cyclic adenosine monophosphate (cAMP), activates protein kinase A (PKA), inhibits Tumor Necrosis Factor (TNF) and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation.Pentoxifylline is also an antagonist at adenosine 2 receptors

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A harmless pill that has no therapeutic effect, used as a control in testing of investigational drug
Study: NCT02290457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: core strength training
Description: Both training programs will last 6 weeks and comprise 2 training sessions per week with a total of 12 training sessions for each intervention group. Each training session will last 30 min, starting with a brief warm-up program mainly consisting of core strength exercises at moderate intensities and ending with a cool-down program (i.e., dynamic stretching). During the main part of training, both groups mainly conduct the big 3 exercises as described by McGill. These will include the curl-up, side bridge, and quadruped position. In other words, every single training session will consist of frontal, dorsal, and lateral core exercises. The only difference between the 2 intervention groups is that the CSTU protocol comprise core exercises that will be conducted on unstable elements (e.g., TOGU© DYNAIR PRO, THERA-BAND© STABILITY TRAINER), whereas the CSTS program will contain the same exercises on stable surface only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: core strength training
Description: Both training programs will last 6 weeks and comprise 2 training sessions per week with a total of 12 training sessions for each intervention group. Each training session will last 30 min, starting with a brief warm-up program mainly consisting of core strength exercises at moderate intensities and ending with a cool-down program (i.e., dynamic stretching). During the main part of training, both groups mainly conduct the big 3 exercises as described by McGill. These will include the curl-up, side bridge, and quadruped position. In other words, every single training session will consist of frontal, dorsal, and lateral core exercises. The only difference between the 2 intervention groups is that the CSTU protocol comprise core exercises that will be conducted on unstable elements (e.g., TOGU© DYNAIR PRO, THERA-BAND© STABILITY TRAINER), whereas the CSTS program will contain the same exercises on stable surface only.
Study: NCT03209817

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red cherry tomato
Description: 300 grams of cherry tomatoes per day for four weeks (each)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yellow cherry tomato
Description: 300 grams of cherry tomatoes per day for four weeks (each)
Study: NCT03874728

Intervention type: OTHER
Intervention: Minimal shoes
Description: A minimal shoe (Vivobarefoot Ltd., London, UK) will be used.

Intervention type: OTHER
Intervention: Standardised conventional shoes
Description: The Go Walk 4.0-Pursuit shoe for women (Skechers USA, Inc.) and the Superior 2.0-Jeveno shoe for men (Skechers USA, Inc) will be used.

Intervention type: OTHER
Intervention: Barefoot
Description: Participants will conduct the assessments barefoot.

Intervention type: OTHER
Intervention: Smart shoe insoles
Description: Arion pressure-measuring insoles (Eindhoven, The Netherlands) will be used in the study.
Study: NCT04638101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: Mindfulness-based intervention: The proposed MBI was designed based on well-known MBI programs including Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy and adapted to adolescents' needs and language. The program consisted of 8 weekly sessions in groups of up to 8 participants, lasting 1h30. Two MBI groups were offered per week (Wednesdays and Fridays) and participants had the possibility to choose the most convenient day for them. Two instructors were present for each group throughout the intervention.For each session one theme was addressed, such as attention and the stabilisation of the focus of attention, bodily sensations, breath, emotions, thoughts, compassion, stress, stress reactivity and coping strategies.
Study: NCT02016482

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00783601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0524 + placebo
Description: Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks
Study: NCT01109147

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Imagery
Description: All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.

Intervention type: OTHER
Group type: OTHER
Intervention: Imagery
Description: All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Imagery
Description: All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: pharmacogenetic sampling
Description: A pharmacogenetic sample will be done with an additional consentment.

Intervention type: GENETIC
Group type: OTHER
Intervention: pharmacogenetic sampling
Description: A pharmacogenetic sample will be done with an additional consentment.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: pharmacogenetic sampling
Description: A pharmacogenetic sample will be done with an additional consentment.
Study: NCT00858182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD solution for nocturnal exchanges
Description: Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients. PD solutions are instilled for 4 weeks.
Study: NCT00783601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0524 + placebo
Description: Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0524 + montelukast
Description: Two 150 mg MK0524 tablets and one 10 mg montelukast tablet once daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0524 + montelukast
Description: Two 150 mg MK0524 tablets and one 10 mg montelukast tablet once daily for 2 weeks
Study: NCT00858182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD solution for diurnal exchanges
Description: Instillation of a PD solution containing xylitol (0.6%), L-carnitine (0.1%) and glucose (0.5%) for the diurnal exchanges in CAPD treated patients. PD solutions are instilled for 4 weeks.
Study: NCT00842205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon
Description: peg-IFN alfa 2a 180ug s.c. QW or peg-IFN alfa 2b 1.5 ug/kg s.c. QW

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavarin
Description: ribavirin 1000-1200mg p.o. daily 48weeks or ribavirin 100-1200mg p.o. daily 48 weeks
Study: NCT01161485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Testing and Counseling
Description: A manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Testing and Counseling
Description: A manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.
Study: NCT04832945

Intervention type: DRUG
Intervention: Ivermectin 6 Mg Oral Tablet
Description: Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks
Study: NCT01275092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorPath robotic-assisted PCI
Description: CorPath 200® robotic-assisted percutaneous coronary intervention
Study: NCT03688243

Intervention type: DEVICE
Intervention: SS-OCT imaging
Description: All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument

Intervention type: DEVICE
Intervention: SS-OCT imaging
Description: All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument

Intervention type: DEVICE
Intervention: SS-OCT imaging
Description: All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
Study: NCT01009749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement System for Adherence (MESA)
Description: MESA is designed to increase motivation for adherence to Highly Active Antiretroviral Therapy (HAART) among youth newly recommended to begin medications.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement System for Health (MESH)
Description: Motivational Enhancement System for Health (MESH) is an attentional control providing information on nutrition and exercise.
Study: NCT03393507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500mg,po, adjusted to 250mg if cannot tolerate, 3 weeks a cycle for a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxus + platinum
Description: Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin. Docetaxel injection dose size of 60-75mg / m2, infusion time of 1 hour; paclitaxel injection dose size 135-175mg / m2, infusion time\> 3 hours; injection of carboplatin dose according to the standard formula Calculated, AUC = 4-5, continued intravenous infusion the next day; cisplatin injection dose size of 75-100mg / m2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxus + platinum
Description: Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin. Docetaxel injection dose size of 60-75mg / m2, infusion time of 1 hour; paclitaxel injection dose size 135-175mg / m2, infusion time\> 3 hours; injection of carboplatin dose according to the standard formula Calculated, AUC = 4-5, continued intravenous infusion the next day; cisplatin injection dose size of 75-100mg / m2.
Study: NCT00605891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmoterol (CHF 4226)
Description: carmoterol pMDI 2.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of carmoterol 1.0 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmoterol (CHF 4226)
Description: carmoterol pMDI 1.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of placebo pMDI))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmoterol (CHF 4226)
Description: carmoterol pMDI 4.0 μg once a day, in the morning~(1 puff of carmoterol 2.0 mcg + 1 puff of carmoterol 2.0 mcg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol
Description: Salmeterol 50 μg DPI, in the morning and in the evening (1 blister BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pMDI once a day, in the morning (1 puff of placebo pMDI + 1 puff of placebo pMDI)
Study: NCT03972410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: 2-4 sessions individual 60-min-long treatment sessions of EMDR Recent birth trauma protocol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SEDP
Description: 2-4 sessions individual 60-min-long treatment sessions of SEDP
Study: NCT00819494

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Skin tests with radiocontrast media
Description: Skin prick tests and intradermal test will be performed in patients with a history of immediate reactions to iodinated radiocontrast media

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin tests with radiocontrast media
Description: Skin prick tests and intradermal test will be performed in patients with a history of immediate reactions to iodinated radiocontrast media
Study: NCT01161485

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Testing and Counseling
Description: A manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.
Study: NCT01458834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention bias modification task
Description: Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (\< or \>). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the active training task, the arrow will replace the neutral pictures 80% of the time.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (\< or \>). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the control training task, the arrow will replace the neutral and smoking-related pictures with equal frequency.
Study: NCT01797380

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for duration of double-blind portion of trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10 mg po daily for duration of double-blind portion of trial
Study: NCT02876328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: 0.5 mL at a dose of 5x10\^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
Study: NCT01161485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: In voucher-based CM programs, drug users who submit urine samples that are negative for specified drugs are reinforced with vouchers. Based on operant conditioning, CM rewards those who comply with the targeted behavior and does not reward when compliance is not achieved. In this study a mid-value reinforcement CM schedule will be used in order to balance community cost concerns with the need to show comparative efficacy in reducing meth use and concomitant sex risk behaviors in a largely unstudied risk group. Participants in the CM arm will be asked to come to the study site three times a week to leave a urine sample, get the result, and will then be offered a voucher if their urine is clean and given brief verbal feedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: In voucher-based CM programs, drug users who submit urine samples that are negative for specified drugs are reinforced with vouchers. Based on operant conditioning, CM rewards those who comply with the targeted behavior and does not reward when compliance is not achieved. In this study a mid-value reinforcement CM schedule will be used in order to balance community cost concerns with the need to show comparative efficacy in reducing meth use and concomitant sex risk behaviors in a largely unstudied risk group. Participants in the CM arm will be asked to come to the study site three times a week to leave a urine sample, get the result, and will then be offered a voucher if their urine is clean and given brief verbal feedback.
Study: NCT02876328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: 0.5 mL at a dose of 1x10\^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP
Description: 1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP
Description: 1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
Study: NCT01161485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengths-based case management
Description: Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community. It differs from more traditional case management models that emphasize resource brokerage and client advocacy in its recognition that only the individual can change his/her behavior.
Study: NCT04520009

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity Restriction
Description: Standard post-operative activity instructions (i.e., no bending, twisting, or lifting more than 10 lbs for 4 weeks, no return to work until cleared to do so).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity as Tolerated
Description: Instructions advising activity as tolerated and return to work based on patient discretion
Study: NCT02876328

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVSV boost
Description: 1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
Study: NCT00645905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded 40 mg eow through Week 48, withdrawal and observation for 360 days after last dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for adalimumab
Description: OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded placebo eow through Week 48, withdrawal and observation for 360 days after last dose
Study: NCT00783601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo + montelukast
Description: Two placebo tablets in the matching image of MK0524 150 mg and one 10 mg tablet montelukast once daily for 2 weeks
Study: NCT03764267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Five minutes before infiltration of the local anesthestic by the surgeon, patients received an initial maintenance infusion of remifentanil 0.1 µg/kg/min and ketofol mixture 0.3 ml/kg (propofol 25 µg /kg/min and ketamine 10 µg/kg/min). ketofol mixture was prepared in a ratio of 1:2.5 (100 mg ketamine 2 mL (100 mg), propofol 1% 25 mL (250 mg), and glucose 5% 23 ml, total volume of 50 ml, each ml contain 2 mg ketamine + 5 mg propofol).~Throughout the surgery, titration of the infusion rate of the remifentanil and ketofol were indicated by vital signs and expression of pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: general anesthetic
Description: general anesthetic was induced with a bolus dose of remifentanil (1 ug/kg over 30 second) and propofol (2 mg/kg) followed by insertion of a laryngeal mask airway (LMA). After the induction of anaesthesia and securing the airway, patient' lungs were ventilated with volume controlled ventilation, 50% oxygen/air mixtures in a circle system. .Anesthesia was maintained with remifentanil (0.5 ug/ kg/ min) and propofol (5 mg/kg/h). Remifentanil and propofol titrated to keep heart rate and the blood pressure within 20% of the baseline values and maintain BIS between 40 and 60, respectively. Patient movements were treated with additional i.v. bolus doses of remifentanil 0.5 ug/kg